New data from Spherix Global Insights show most physicians view patients as gene therapy candidates, yet few have initiated the treatment regime Exton,
The decision is made off findings from the 2 phase 3, randomized, double-blind, placebo-controlled POETYK PsA-1 and POETYK PsA-2 trials.
A patient audit of more than 1,000 lupus nephritis charts highlights growing experience with biologics and calcineurin inhibitors, alongside rising
Recently released data finds 22% of patients are not optimally managed despite growing use of Novartis’ Fabhalta, Alexion’s Voydeya, and
EXTON, PA, March 3, 2026 — Spherix Global Insights today announced the launch of a new suite of services focused
After UCB’s Bimzelx scored five approvals in just two years, the Belgian drugmaker has quickly made a blockbuster out of
Findings show strong pre-launch awareness, safety-driven TYK2 differentiation from JAK inhibitors, and opportunity for Bristol Myers Squibb to strengthen rheumatology
Strong clinical advance perceptions and anticipated displacement of other IgAN-targeted therapies position Voyxact for meaningful early momentum, according to the
Awareness and prescribing of the Wegovy pill for weight loss surge among primary care physicians and endocrinologists following its January
Initial uptake reflects strong efficacy-driven positioning relative to established therapies, though familiarity gaps, payer controls, and measured promotional visibility shape
New Patient Voice Dynamix™ research highlights that even with patients’ high awareness of options and active engagement in their care,
The FDA has rejected AstraZeneca’s subcutaneous version of lupus treatment Saphnelo, but the company is moving quickly to address the
